BIOMAT Database Logo BIOMAT Database Logo

Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man. 1987

C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232.

UI MeSH Term Description Entries
D008297 Male Males
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone
D015764 Bepridil A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. 1978-CERM,Bedapin,Bepadin,Bepridil Monohydrochloride,Bepridil Monohydrochloride, Monohydrate,Bepridil Monohydrochloride, alpha-Isomer,Bepridil, (+)-Isomer,Bepridil, (+-)-Isomer,Bepridil, (-)-Isomer,Bepridil, alpha-Isomer,CERM-1978,Cordium,Unicordium,Vascor,1978 CERM,1978CERM,Bepridil Monohydrochloride, alpha Isomer,Bepridil, alpha Isomer,CERM 1978,CERM1978,Monohydrochloride, Bepridil,Monohydrochloride, alpha-Isomer Bepridil

Related Publications

C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Bepridil: a new long-acting calcium channel blocking agent.
June 1987, Drug intelligence & clinical pharmacy,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
The effect of a calcium-channel blocking agent on intraocular pressure.
December 1983, American journal of ophthalmology,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Inhibitory effect of isoniazid on antipyrine clearance in man.
January 1983, Journal of clinical pharmacology,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Selecting a calcium channel-blocking agent.
April 1987, Canadian family physician Medecin de famille canadien,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
The effect of oral verapamil therapy on antipyrine clearance.
November 1986, British journal of clinical pharmacology,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Pharmacologic characterization of FR172516: a new combined calcium channel-blocking and beta-adrenoceptor-blocking agent.
April 1999, Journal of cardiovascular pharmacology,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.
January 1980, Arzneimittel-Forschung,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Cardiac electrophysiologic effects of McN-5691, a new calcium-channel blocking antihypertensive agent.
October 1990, Journal of cardiovascular pharmacology,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension.
March 1983, The American journal of cardiology,
C Funck-Brentano, and P L Chaffin, and G R Wilkinson, and B McAllister, and R L Woosley
Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties.
September 1983, European heart journal,
Copied contents to your clipboard!